Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNLI NASDAQ:JBIO NASDAQ:NAMS NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$22.65-14.5%$22.02$12.58▼$27.30$4.20B0.961.75 million shs5.78 million shsJBIOJade Biosciences$21.34+0.2%$20.68$6.67▼$28.00$1.05B1.431.29 million shs1.22 million shsNAMSNewAmsterdam Pharma$33.29+0.0%$33.69$20.53▼$42.21$3.89B0.08997,927 shs607,060 shsTNGXTango Therapeutics$29.65+4.5%$26.34$5.77▼$34.39$4.10B1.124.46 million shs1.93 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics-14.46%-13.91%+4.57%+4.47%+54.19%JBIOJade Biosciences+0.19%-4.94%+39.11%+10.80%+137.11%NAMSNewAmsterdam Pharma+0.03%-10.00%+9.51%-2.12%+50.16%TNGXTango Therapeutics+4.55%-1.56%-4.17%+17.05%+386.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$22.65-14.5%$22.02$12.58▼$27.30$4.20B0.961.75 million shs5.78 million shsJBIOJade Biosciences$21.34+0.2%$20.68$6.67▼$28.00$1.05B1.431.29 million shs1.22 million shsNAMSNewAmsterdam Pharma$33.29+0.0%$33.69$20.53▼$42.21$3.89B0.08997,927 shs607,060 shsTNGXTango Therapeutics$29.65+4.5%$26.34$5.77▼$34.39$4.10B1.124.46 million shs1.93 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics-14.46%-13.91%+4.57%+4.47%+54.19%JBIOJade Biosciences+0.19%-4.94%+39.11%+10.80%+137.11%NAMSNewAmsterdam Pharma+0.03%-10.00%+9.51%-2.12%+50.16%TNGXTango Therapeutics+4.55%-1.56%-4.17%+17.05%+386.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNLIDenali Therapeutics 2.81Moderate Buy$34.7553.42% UpsideJBIOJade Biosciences 2.90Moderate Buy$51.57141.67% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$49.0047.19% UpsideTNGXTango Therapeutics 2.75Moderate Buy$41.8541.13% UpsideCurrent Analyst Ratings BreakdownLatest JBIO, TNGX, DNLI, and NAMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026TNGXTango Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$46.007/13/2026DNLIDenali Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$26.007/13/2026DNLIDenali Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$29.006/30/2026NAMSNewAmsterdam Pharma Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$47.00 ➝ $51.006/29/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/29/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $46.006/25/2026TNGXTango Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$27.00 ➝ $60.006/25/2026TNGXTango Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold6/22/2026DNLIDenali Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$41.006/22/2026DNLIDenali Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/16/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNLIDenali Therapeutics$330.53M10.88N/AN/A$6.91 per share3.28JBIOJade BiosciencesN/AN/AN/AN/A$6.74 per shareN/ANAMSNewAmsterdam Pharma$22.50M172.96N/AN/A$5.97 per share5.58TNGXTango Therapeutics$62.38M68.75N/AN/A$2.57 per share11.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)JBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/ANAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)TNGXTango Therapeutics-$101.59M-$0.83N/AN/AN/AN/A-41.54%-33.44%8/4/2026 (Estimated)Latest JBIO, TNGX, DNLI, and NAMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026DNLIDenali Therapeutics-$0.73N/AN/AN/A$2.15 millionN/A8/5/2026Q2 2026NAMSNewAmsterdam Pharma-$0.48N/AN/AN/A$1.79 millionN/A8/4/2026Q2 2026TNGXTango Therapeutics-$0.31N/AN/AN/A$1.56 millionN/A5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNLIDenali TherapeuticsN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNLIDenali Therapeutics0.019.289.28JBIOJade BiosciencesN/A14.2914.29NAMSNewAmsterdam PharmaN/A9.769.76TNGXTango TherapeuticsN/A27.3827.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNLIDenali Therapeutics92.92%JBIOJade BiosciencesN/ANAMSNewAmsterdam Pharma89.89%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipDNLIDenali Therapeutics12.50%JBIOJade Biosciences23.06%NAMSNewAmsterdam Pharma12.74%TNGXTango Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableJBIOJade Biosciences2049.36 million37.98 millionN/ANAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableTNGXTango Therapeutics90144.65 million135.25 millionOptionableJBIO, TNGX, DNLI, and NAMS HeadlinesRecent News About These CompaniesJPMorgan Chase & Co. Initiates Coverage on Tango Therapeutics (NASDAQ:TNGX)11 minutes ago | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Shares Down 8.7% - Here's What HappenedJuly 13 at 3:59 PM | marketbeat.comCandriam S.C.A. Purchases 560,434 Shares of Tango Therapeutics, Inc. $TNGXJuly 12 at 10:56 AM | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 9, 2026 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Insider Sells $798,930.00 in StockJuly 5, 2026 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 27,000 Shares of StockJuly 3, 2026 | insidertrades.comIs TNGX Stock Still Worth Buying After Its Huge Rally in 2026?July 2, 2026 | zacks.comTango Therapeutics Rides a New Precision Oncology Trend in 2026July 2, 2026 | zacks.comTNGX Stock Outlook Hinges on Vopimetostat and Key 2026 CatalystsJuly 2, 2026 | zacks.comTango Therapeutics Appoints Robert Azelby to Board of DirectorsJune 22, 2026 | globenewswire.comIs Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One YearJune 10, 2026 | finance.yahoo.comTango Therapeutics Announces Major Underwritten Equity OfferingJune 10, 2026 | tipranks.comTango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsJune 9, 2026 | quiverquant.comQTango Therapeutics Announces Pricing of $600 Million Upsized Public OfferingJune 9, 2026 | globenewswire.comTango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk AppetiteJune 9, 2026 | seekingalpha.comTango Therapeutics (TNGX) stock soars on pancreatic cancer trial resultsJune 9, 2026 | msn.comTNGX Stock Jumps 53% on Early Pancreatic Cancer Study ResultsJune 9, 2026 | zacks.comTango shares surge on early pancreatic cancer combination dataJune 9, 2026 | thepharmaletter.comTTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer TranscriptJune 8, 2026 | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8, 2026 | invezz.comITango Therapeutics Announces Proposed $500 Million Public OfferingJune 8, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJBIO, TNGX, DNLI, and NAMS Company DescriptionsDenali Therapeutics NASDAQ:DNLI$22.65 -3.83 (-14.46%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$22.59 -0.06 (-0.28%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Jade Biosciences NASDAQ:JBIO$21.34 +0.04 (+0.19%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$20.56 -0.77 (-3.63%) As of 07:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.NewAmsterdam Pharma NASDAQ:NAMS$33.29 +0.01 (+0.03%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$33.16 -0.13 (-0.38%) As of 07:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Tango Therapeutics NASDAQ:TNGX$29.65 +1.29 (+4.55%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$30.18 +0.54 (+1.80%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
